NO20013599D0 - HIV-1-mutasjoner selektert for av <beta>-2',3'-dideoksy-5- fluorcytidin - Google Patents

HIV-1-mutasjoner selektert for av <beta>-2',3'-dideoksy-5- fluorcytidin

Info

Publication number
NO20013599D0
NO20013599D0 NO20013599A NO20013599A NO20013599D0 NO 20013599 D0 NO20013599 D0 NO 20013599D0 NO 20013599 A NO20013599 A NO 20013599A NO 20013599 A NO20013599 A NO 20013599A NO 20013599 D0 NO20013599 D0 NO 20013599D0
Authority
NO
Norway
Prior art keywords
beta
hiv
d4fc
drug
fluorocytidine
Prior art date
Application number
NO20013599A
Other languages
English (en)
Other versions
NO323586B1 (no
NO20013599L (no
Inventor
Raymond F Schinazi
Jennifer Hammond
John W Mellors
Dennis C Liotta
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of NO20013599D0 publication Critical patent/NO20013599D0/no
Publication of NO20013599L publication Critical patent/NO20013599L/no
Publication of NO323586B1 publication Critical patent/NO323586B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20013599A 1999-01-22 2001-07-20 Farmasoytisk sammensetning omfattende b-D-D4FC og abacavir for behandling eller forebyggelse av HIV-infeksjon hos mennesker NO323586B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22
PCT/US2000/001738 WO2000043014A2 (en) 1999-01-22 2000-01-21 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections

Publications (3)

Publication Number Publication Date
NO20013599D0 true NO20013599D0 (no) 2001-07-20
NO20013599L NO20013599L (no) 2001-09-20
NO323586B1 NO323586B1 (no) 2007-06-11

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013599A NO323586B1 (no) 1999-01-22 2001-07-20 Farmasoytisk sammensetning omfattende b-D-D4FC og abacavir for behandling eller forebyggelse av HIV-infeksjon hos mennesker

Country Status (21)

Country Link
EP (1) EP1143976B9 (no)
JP (1) JP2002535278A (no)
KR (1) KR100745408B1 (no)
CN (2) CN1337880A (no)
AT (1) ATE324894T1 (no)
AU (1) AU781281B2 (no)
BR (1) BR0007627A (no)
CA (1) CA2360039C (no)
DE (1) DE60027691T2 (no)
DK (1) DK1143976T3 (no)
ES (1) ES2263449T3 (no)
HK (1) HK1040064B (no)
IL (1) IL144382A (no)
MX (1) MXPA01007359A (no)
NO (1) NO323586B1 (no)
NZ (1) NZ528156A (no)
PL (1) PL198237B1 (no)
PT (1) PT1143976E (no)
RU (1) RU2254133C2 (no)
WO (1) WO2000043014A2 (no)
ZA (1) ZA200105971B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003239088B2 (en) * 2002-06-27 2006-11-02 Medivir Ab Synergistic interaction of abacavir and alovudine
US20050244490A1 (en) * 2003-12-09 2005-11-03 Michael Otto Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
US7741334B2 (en) 2004-04-01 2010-06-22 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
WO2006044968A2 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
JP2002518452A (ja) * 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用

Also Published As

Publication number Publication date
KR20020068260A (ko) 2002-08-27
NO323586B1 (no) 2007-06-11
CN1337880A (zh) 2002-02-27
NO20013599L (no) 2001-09-20
CN101219148A (zh) 2008-07-16
JP2002535278A (ja) 2002-10-22
WO2000043014A2 (en) 2000-07-27
EP1143976A2 (en) 2001-10-17
ZA200105971B (en) 2002-10-21
CA2360039A1 (en) 2000-07-27
IL144382A0 (en) 2002-05-23
MXPA01007359A (es) 2003-09-22
PT1143976E (pt) 2006-09-29
DE60027691T2 (de) 2007-04-12
RU2254133C2 (ru) 2005-06-20
HK1040064A1 (en) 2002-05-24
ATE324894T1 (de) 2006-06-15
AU2627000A (en) 2000-08-07
BR0007627A (pt) 2002-04-09
EP1143976B9 (en) 2007-02-14
NZ528156A (en) 2005-03-24
CA2360039C (en) 2009-11-24
KR100745408B1 (ko) 2007-08-02
EP1143976B1 (en) 2006-05-03
IL144382A (en) 2007-02-11
DK1143976T3 (da) 2006-09-04
WO2000043014A8 (en) 2001-01-18
ES2263449T3 (es) 2006-12-16
AU781281B2 (en) 2005-05-12
PL198237B1 (pl) 2008-06-30
DE60027691D1 (de) 2006-06-08
HK1040064B (zh) 2006-07-21
WO2000043014A3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3&#39;-azido-2&#39;,3&#39;-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
Baltodano et al. Verapamil vs quinine in recumbent nocturnal leg cramps in the elderly
AP2000001991A0 (en) 3-(Amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases.
JP2002528502A5 (no)
YU27203A (sh) Pirazol derivati za tretiranje virusnih oboljenja
BG105173A (en) Novel salt form of pantoprazole
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3&#39;-디옥시티미딘-2&#39;-엔(3&#39;-디옥시-2&#39;,3&#39;-디디하이드로티미딘)의 사용법
DK0658110T3 (da) Anvendelse af norastemizol til behandling af allergisk rhinitis
NO20013599D0 (no) HIV-1-mutasjoner selektert for av &lt;beta&gt;-2&#39;,3&#39;-dideoksy-5- fluorcytidin
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
DE69328667D1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
EP1731155A3 (en) Beta-d-2&#39;, 3&#39; -didehydro-2&#39;, 3&#39; -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
KR930702985A (ko) 식도암의 치료
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
KR890001555A (ko) 요산 배설용 조성물
JPS62265227A (ja) 薬剤性末梢神経障害の予防・治療剤
DK1265629T3 (da) Anvendelse af væksthormon i lav dosis
James PMPA--first human results
RU2000104538A (ru) Способ эндопротезирования тазобедренного сустава при последствиях метатуберкулезного коксита
HUP0402118A2 (hu) Propionil-L-karnitin vagy gyógyászatilag elfogadható sója, alkalmazása peyronie-betegség kezelésére szánt gyógyászati készítmény előállítására
TH77071A (th) สารประกอบชนิดไพราโซลิดีนอล
NO931338L (no) Forbindelser og fremgangsmaater for inhibering av hiv og beslektede virus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees